Pricing & Reimbursement


Pricing & Reimbursement, Wednesday 24 April 2024

Dean Suhr
Pricing & Reimbursement

Chair's Remarks

Marshall Summar
Pricing & Reimbursement

Strategies to save time and cost in rare disease drug development

Marshall Summar, Chief Executive Officer, Uncommon Cures
Kyle Clifton
Pricing & Reimbursement

Potential for optimal patient access and reimbursement

Panel discussion
Pricing & Reimbursement

Pricing, reimbursement and payer challenges for rare diseases in the US

Moderator: Kollet Koulianos, Senior Payor Advisor, National Hemophilia Foundation
Durhane Wong-Rieger, President, Chief Executive Officer & Chair, Canadian Organisation for Rare Disorder & Rare Diseases International
Kristin Viswanathan Wolff, Senior Director, Global Government Affairs And Public Policy, bluebird bio
Panel discussion
Pricing & Reimbursement

Innovative financing solutions for rare disease treatments: Balancing cost, access, and sustainability

Moderator: Mark Trusheim, Strategic Director NEWDIGS, Center for Biomedical System Design, Tufts Medical Center
Steven Peskin, President and Chief Executive Officer; Former Executive Medical Director Population Health, Horizon Blue Cross Blue Shield of NJ, SRP Advisors, LLC
Kollet Koulianos, Senior Payor Advisor, National Hemophilia Foundation
Alexander Natz
Pricing & Reimbursement

Pricing challenges for rare diseases in Europe

Alexander Natz, Director General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Jin Ding
Pricing & Reimbursement

The growing divergence in orphan approvals: A retrospective cohort study comparing the FDA and the EMA from 2011 to 2020

Panel discussion
last published: 20/Apr/24 16:35



Get Involved At World Orphan Drug Congress USA


To Sponsor Or Exhibit


Justin Franks
t/ +1 914 819 3506




To Speak


Gina McHugh
t/ +1 646 619 1775




Marketing & Press Opportunities


Kaylie Brogan